Importantly, these clinical data directly correlate with our ex vivo findings clearly revealing a protective role for HMGA2 against TOP2A targeting drugs and, taken together, illustrates their importance for clinical strategies in particular for HMGA2‐positive AML patients. Here, HMGA2 is linked to acute myeloid leukemia.